Lithium interaction with sulindac and naproxen.
The interaction of lithium with sulindac and naproxen was studied in six sulindac-treated and seven naproxen-treated patients admitted to a geropsychiatry ward. Patients under a steady state lithium level received lithium for 3 days, then lithium + sulindac (300 mg/day) or naproxen (750 mg/day) for 6 days, and then lithium alone for 5 days. Sulindac failed to affect serum lithium levels and lithium clearance. The results with naproxen showed marked interindividual variations ranging from no increase to a 41.9% increase in serum lithium levels within 5 days. There was a corresponding decrease in lithium clearance in naproxen-treated patients. Patients undergoing lithium therapy might need a reduction of their lithium dosage following naproxen administration. More frequent serum lithium level determinations are required following initiation of naproxen therapy until the magnitude of the lithium-naproxen drug interaction can be adequately assessed in a given individual.